Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates.

NERVIANO, Italy, June 5, 2023 /PRNewswire/ — Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS Group S.p.A. (NMS group), the largest cancer research and development company in Italy, announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) … Read more